Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ira Pastan

Showing results (51-60 of 340) with videos related to

Pageof 34
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2011
Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapyRajat Singh, Yujian Zhang, Ira Pastan, et al.
Oncotarget|November 21, 2017
Panbinostat decreases cFLIP and enhances killing of cancer cells by immunotoxin LMB-100 by stimulating the extrinsic apoptotic pathwayXiu-Fen Liu, Qi Zhou, Raffit Hassan, et al.
Receptors & Clinical Investigation|March 14, 2017
EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced deliveryXuhui Bao, Ira Pastan, Darell D Bigner, et al.
Molecular Cancer Therapeutics|March 5, 2016
Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based ImmunotoxinsXiufen Liu, Fabian Müller, Alan S Wayne, et al.
Bioconjugate Chemistry|March 20, 2003
Mutants of immunotoxin anti-Tac(dsFv)-PE38 with variable number of lysine residues as candidates for site-specific chemical modification. 1. Properties of mutant moleculesMasanori Onda, James J Vincent, Byungkook Lee, et al.
Molecular Cancer Therapeutics|December 14, 2002
Characterization of overlapping XAGE-1 transcripts encoding a cancer testis antigen expressed in lung, breast, and other types of cancersKristi A Egland, Vasantha Kumar, Paul Duray, et al.
Molecular Cancer Therapeutics|February 22, 2012
Mesothelin-targeted agents in clinical trials and in preclinical developmentRonan J Kelly, Elad Sharon, Ira Pastan, et al.
The Journal of Biological Chemistry|October 20, 2004
In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxinMitchell Ho, Robert J Kreitman, Masanori Onda, et al.
Leukemia & Lymphoma|October 10, 2009
Approach to the patient after relapse of hairy cell leukemiaRobert J Kreitman, David J P Fitzgerald, Ira Pastan
Journal of Immunological Methods|June 10, 2015
Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin ARonit Mazor, Chin-Hsien Tai, Byungkook Lee, et al.
Pageof 34

Showing results (51-60 of 340) with videos related to

Sort By:
Pageof 34
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2011
Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapyRajat Singh, Yujian Zhang, Ira Pastan, et al.
Oncotarget|November 21, 2017
Panbinostat decreases cFLIP and enhances killing of cancer cells by immunotoxin LMB-100 by stimulating the extrinsic apoptotic pathwayXiu-Fen Liu, Qi Zhou, Raffit Hassan, et al.
Receptors & Clinical Investigation|March 14, 2017
EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced deliveryXuhui Bao, Ira Pastan, Darell D Bigner, et al.
Molecular Cancer Therapeutics|March 5, 2016
Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based ImmunotoxinsXiufen Liu, Fabian Müller, Alan S Wayne, et al.
Bioconjugate Chemistry|March 20, 2003
Mutants of immunotoxin anti-Tac(dsFv)-PE38 with variable number of lysine residues as candidates for site-specific chemical modification. 1. Properties of mutant moleculesMasanori Onda, James J Vincent, Byungkook Lee, et al.
Molecular Cancer Therapeutics|December 14, 2002
Characterization of overlapping XAGE-1 transcripts encoding a cancer testis antigen expressed in lung, breast, and other types of cancersKristi A Egland, Vasantha Kumar, Paul Duray, et al.
Molecular Cancer Therapeutics|February 22, 2012
Mesothelin-targeted agents in clinical trials and in preclinical developmentRonan J Kelly, Elad Sharon, Ira Pastan, et al.
The Journal of Biological Chemistry|October 20, 2004
In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxinMitchell Ho, Robert J Kreitman, Masanori Onda, et al.
Leukemia & Lymphoma|October 10, 2009
Approach to the patient after relapse of hairy cell leukemiaRobert J Kreitman, David J P Fitzgerald, Ira Pastan
Journal of Immunological Methods|June 10, 2015
Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin ARonit Mazor, Chin-Hsien Tai, Byungkook Lee, et al.
Pageof 34